Dianne M Finkelstein

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. Skates S, Mai P, Horick N, Piedmonte M, Drescher C, Isaacs C, et al. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila). 2011;4:1401-8 pubmed publisher
  2. Strasser Weippl K, Horick N, Smith I, O Shaughnessy J, Ejlertsen B, Boyle F, et al. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res. 2015;17:56 pubmed publisher
    ..The event rates shown for subpopulations of HER2+ BC patients suggest that in resource-constrained environments patients with HER2+ HR- early BC should be prioritized for consideration of adjuvant anti-HER2 therapy. ..
  3. Strasser Weippl K, Horick N, Smith I, O Shaughnessy J, Ejlertsen B, Boyle F, et al. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. Eur J Cancer. 2016;56:85-92 pubmed publisher
    ..NNT in HER2+ HR- patients are in range with those reported from up-front adjuvant trastuzumab trials. ..
  4. Schoenfeld D, Finkelstein D. Assessing survival benefit when treatment delays disease progression. Clin Trials. 2016;13:352-7 pubmed publisher
    ..For a clinical trial for which treatment delays progression, the proposed method can improve the interpretability of the survival comparison using data from the study. ..